Skip to content

CG Oncology CGON Net gains (losses) on investments

Net gains (losses) on investments at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$180K-1,536%
Biogen logo
BiogenBIIB
$19M+146%
Incyte logo
IncyteINCY
$6.59M+591%

Other financials

Income statement

See full
Revenue$1.1M+1,983%
Operating income-$66.4M-57.3%
Net income-$60.2M-74.7%
EPS (diluted)-$0.71-57.8%

Balance sheet

See full
Cash & equivalents$33.7M-18.7%
Total debt$7.6M+631%
Total equity$1.1B+54.9%
Total assets$1.1B+55.9%

Cash flow

See full
Operating cash flow-$56.9M-94.5%
CapEx$304.0K+1,800%
Free cash flow-$57.2M-95.4%

Valuation

See full
Market cap$5.8B+206%

Profitability

See full
Operating margin-4,239%-1,872pp
Net margin-3,682.6%-1,601pp
FCF margin-3,163.8%-1,351pp

Returns & leverage

See full
Return on equity-20.8%+7.1pp
Debt / equity0.0×
Current ratio31.3×+0.3×

Where this comes from

Reported directly by CG Oncology in its filing.

Tagged under the XBRL concept us-gaap:UnrealizedGainLossOnInvestments.

The official record: CG Oncology’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about CG Oncology's net gains (losses) on investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CG Oncology's net gains (losses) on investments?
CG Oncology (CGON) reported net gains (losses) on investments of -$1.66M in Q1 2026.
What does net gains (losses) on investments mean?
Realized and unrealized gains/losses on investments removed from operating cash flow since they're investing-related.